About maplight therapeutics inc - MPLT
MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for brain disorders. It develops the ML-007-MA product for treatment of schizophrenia and ADP. Its platforms include Optogenetics, Transcriptnomics, and STARmap. The company was founded by Christopher A. Kroeger, Karl Deisseroth, Robert Malenka, and Karoly Nikolich in November 2018 and is headquartered in Redwood City, CA.
MPLT At a Glance
MapLight Therapeutics, Inc.
800 Chesapeake Drive
Redwood City, California 94063
| Phone | 1-617-984-6300 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -161,152,000.00 | |
| Sector | Health Technology | Employees | 133 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MPLT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.687 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -2.813 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.012 |
MPLT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,211,669.173 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
MPLT Liquidity
| Current Ratio | 20.006 |
| Quick Ratio | 20.006 |
| Cash Ratio | 18.80 |
MPLT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -52.286 |
| Return on Equity | -56.193 |
| Return on Total Capital | -34.718 |
| Return on Invested Capital | -55.163 |
MPLT Capital Structure
| Total Debt to Total Equity | 1.266 |
| Total Debt to Total Capital | 1.25 |
| Total Debt to Total Assets | 1.21 |
| Long-Term Debt to Equity | 1.071 |
| Long-Term Debt to Total Capital | 1.058 |